Lung cancer trials in Canada

In Canada 156 Also abroad 2729

156 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Montreal
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Halifax, Hamilton, Kingston, Montreal, Oshawa, Québec, Toronto
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
No phaseTaking people
General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound
Where
Québec
Age
18 years and over
People
306 worldwide
Run by
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06950515
Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Hamilton, Kingston, Montreal, Ottawa
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Montreal
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Edmonton, Ottawa, Toronto, Vancouver
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Halifax, Montreal, Québec, Regina, Saskatoon, Toronto
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 1Taking people
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Where
Toronto
Age
18 years to 99 years
People
600 worldwide
Run by
Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00
Phase 1/2Taking people
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Where
Toronto
Age
18 years and over
People
315 worldwide
Run by
Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00
Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Montreal, Ottawa, Toronto
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Barrie, Brampton, Kelowna, Montreal, Ottawa, Québec, Rimouski, Saskatoon, Victoria
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 2Taking people
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
Where
Edmonton
Age
18 years and over
People
58
Run by
AHS Cancer Control Alberta
See details and how to joinNCT06882174
Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Where
Montreal, Toronto
Age
18 years and over
People
540 worldwide
Run by
Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Calgary, Greenfield Park, Laval, Montreal, Oshawa, Québec, Saint-Jérôme, Toronto
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Montreal, Ottawa, Québec
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 2/3Not yet taking people in Canada
A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer
Where
London
Age
18 years and over
People
150
Run by
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
See details and how to joinNCT07920549
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Abbotsford British Columbia, Chicoutimi, Vancouver
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Brampton, Montreal, Toronto, Vancouver
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 1/2Taking people
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Where
Edmonton, Toronto
Age
18 years and over
People
675 worldwide
Run by
BlossomHill Therapeutics
See details and how to joinNCT06706076
Phase 2Not yet taking people in Canada
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
Where
Toronto
Age
18 years and over
People
60
Run by
University Health Network, Toronto
See details and how to joinNCT06813664
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Toronto, Vancouver
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Toronto
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
Where
Edmonton
Age
18 years and over
People
31
Run by
AHS Cancer Control Alberta
See details and how to joinNCT04952480
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Brampton, Mississauga, Montreal
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00
Phase 1/2Taking people
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Where
Toronto
Age
18 years and over
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227025